Jump to Navigation

Facebook Connect

User login

Journal of Clinical Lipidology Sees Increase in Impact Factor

The 2014 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw another increase — from 3.587 (2013) to 3.904 (2014). The Journal is now ranked 44th out of 254 journals in its category (pharmacology and pharmacy). The Thomson-Reuters Impact Factor... read more

Cardiology Today's Featured Meeting Coverage

Visit Cardiology Today's resource page to view meeting highlights from the National Lipid Association's 2015 Scientific... read more

Memorial Wall: NLA Honors Past Leaders in Lipidology

Make sure to check out the Memorial Wall online, where the National Lipid Association posthumously honors those past leaders and pioneers who have helped shape the field of Clinical Lipidology. The first Memorial Wall was displayed at this year's Scientific Sessions and will be updated every... read more

2015 NLA Scientific Sessions Meeting Coverage

The National Lipid Association 2015 Scientific Sessions has concluded, however, you can still review featured highlights from selected presentations. Visit out Meeting Coverage page to view highlights from all four days of sessions. Read our meeting coverage... read more

E-Poster Hall for 2015 NLA Scientific Sessions

Visit the NLA's E-Poster Hall to view this year's submitted abstracts for the 2015 Scientific Sessions in Chicago. The NLA E-Poster Hall includes a vast array of topics in 16 categories, including clinical applications of biomarkers, epidemiology of cardiovascular disease, management of statin... read more

NLA Statement on the IMPROVE-IT Study Findings: Results Support the NLA Recommendations that Lower Is Better

On June 3, 2015, the anticipated final results of the IMProved Reduction of Outcomes: Vytorin Efficacy I... read more

PCSK9 Inhibitors – One Big Step Closer to Approval by the FDA

Two new PCSK9 monoclonal antibodies have been given a nod of approval to the Food and Drug Administration (FDA). The FDA Endocrinologic and Metabolic Drugs Advisory Committee reviewed the evidence on the new class of cholesterol-lowering drugs and recommended that the FDA should approve the new... read more



by Dr. Radut.